Psoriasis: Targets and Therapy (Oct 2024)

Metabolic Syndrome in Psoriasis and Psoriatic Arthritis in a Mixed Race Population: Comparison of Their Prevalences

  • Acioly PMG,
  • Mazzillo MDLT,
  • Machado CJ,
  • Camargo C,
  • Penetra MA,
  • Januário V,
  • Reis BRD,
  • Ramos-e-Silva M,
  • Carneiro S

Journal volume & issue
Vol. Volume 14
pp. 123 – 130

Abstract

Read online

Patrícia Medeiros Gusmão Acioly,1,2 Mara Diane Lisboa Tavares Mazzillo,1,2 Carla Jorge Machado,3 Cláudia Camargo,2 Maria Alice Penetra,2 Virginia Januário,2 Beatriz Ribeiro dos Reis,1 Marcia Ramos-e-Silva,1 Sueli Carneiro1,2 1Sector of Dermatology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil; 2Postgraduation Program in Medical Clinics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; 3Department of Preventive and Social Medicine, Federal University of Minas Gerais, Belo Horizonte, BrazilCorrespondence: Patrícia Medeiros Gusmão Acioly, Email [email protected]: There is a growing body of evidence suggesting the association between psoriasis (PsO) and psoriatic arthritis (PsA) separately with metabolic syndrome (MS) in different populations. The literature is relatively scarce in terms of comparing the prevalence of MS in PsO and PsA with controls without systemic inflammatory diseases.Objective: We aimed to assess the prevalence of MS among patients with PsO, PsA, and a control group without systemic inflammatory disease, in addition to investigating the risks of MS occurrence and its different components in each group.Methods: This is a cross-sectional case-control study with three groups of patients: PsO, PsA, and control. The diagnosis of MS was defined according to the modified 2009 NCTEP ATP III criteria. Patients underwent thorough physical examination and fasting blood samples.Results: A total of 195 patients were included in this analysis (PsO = 50; PsA = 64, and controls = 81). The prevalence of MS in the control, PsO, and PsA groups was 37%, 56%, and 57.8%, respectively (p < 0.001). Waist circumference (p = 0.013) and arterial hypertension (p < 0.001) were the most significant components of MS in patients with PsO and PsA. Multivariate analysis confirmed an independent risk of MS in women, elderly patients, obese patients, patients with hyperglycemia, and patients with psoriasis, especially PsA (OR = 6.2 [CI 95% 2.4– 16.2], p < 0.001).Conclusion: MS is more prevalent in patients with PsA, which can be determined by the increase in inflammatory pathways.Keywords: metabolic syndrome, obesity, prevalence, psoriasis, psoriatic arthritis

Keywords